Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InnoCare Doses First Patient In Study Of ICP-189 Combined With Furmonertinib
Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.
Brand Name : ICP-189
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2024
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
ArriVent Announces Pricing of Upsized Initial Public Offering
Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA
Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-sele...
Brand Name : ICP-189
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Arrivent
Deal Size : Undisclosed
Deal Type : Collaboration
InnoCare and ArriVent Announce Clinical Development Collaboration
Details : Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in...
Brand Name : ICP-189
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Arrivent
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal
Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Brand Name : ABK3376
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2022
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?